Secukinumab improves patient‐reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo‐controlled clinical trials
International Journal of Dermatology2016Vol. 55(4), pp. 401–407
Citations Over TimeTop 10% of 2016 papers
Bruce Strober, Bárður Sigurgeirsson, Georg Popp, Rodney Sinclair, James Krell, Sigitas Stonkus, Marcis Septe, Boni E. Elewski, Alice B. Gottlieb, Yang Zhao, Mary Helen Tran, Alexander Karpov, Lori McLeod, Margaret Mordin, C. Papavassilis, Judit Nyirady, Mark Lebwohl
Abstract
Secukinumab significantly improves patient-reported itching, pain, and scaling in adults with moderate to severe psoriasis compared with placebo.
Related Papers
- → A Review of Secukinumab in Psoriasis Treatment(2020)22 cited
- → Secukinumab (AIN-457) for the treatment of Psoriasis(2015)13 cited
- → Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs(2021)4 cited
- → AB0639 TREATMENT EFFICACY WITH SECUKINUMAB IN A COHORT OF SPONDYLOARTHRITIS PATIENTS(2020)
- → 17731 Evolving resolution of clinical, cellular, and transcriptomic inflammatory markers during 1-year IL-17A inhibition by secukinumab(2020)